Although tremendous progress has been made in managing and treating cancer patients, it is still the case that many tumours that initially respond to chemotherapy will eventually become resistant. Predicting and overcoming such resistance is critical to patient outcomes. To design and develop new drugs-and to select treatments that are most likely to help patients based on specific genotypes-scientists need a better genetic understanding of tumours’ mechanisms. Achieving such an understanding is the focus of Dr. Artem Cherkasov’s research.
As Canada Research Chair in Precision Cancer Drug Design, Cherkasov is using innovation and collaboration to make critical advances in precision drug design and discovery. Ultimately, he and his research team aim to contribute to a more patient-oriented, innovative and effective health-care system.